Previsione rapida della risposta ai farmaci in vivo utilizzando innesti di cellule leucemiche in embrioni di zebrafish

Overview

This protocol outlines a rapid seven-day workflow for assessing drug responses in human acute lymphoblastic leukemia (ALL) using zebrafish embryos. It details the generation of xenografts from patient-derived leukemia cells and provides insights into adapting the method for solid tumors.

Key Study Components

Area of Science

• Oncology
• Pharmacology
• Preclinical Models

Background

• Human acute lymphoblastic leukemia (ALL) is a pediatric cancer.
• Zebrafish embryos serve as a unique preclinical model for studying cancer.
• Access to rare cancer samples enhances the relevance of the study.
• Drug penetration and pharmacokinetics are critical for effective treatment assessment.

Purpose of Study

• To develop a protocol for generating xenografts from ALL and solid tumors.
• To evaluate drug responses in a clinically relevant model.
• To improve the survival of graft cells by blocking immune differentiation.

Methods Used

• Generation of xenografts from cell lines and fresh patient material.
• Transient immunosuppression of zebrafish embryos.
• Flow cytometry for assessing single cell viability and proliferation.
• Testing drug penetration before experimental trials.

Main Results

• Successful growth of patient-derived leukemia cells in zebrafish.
• Adaptation of the protocol for solid pediatric tumors.
• Effective measurement of drug responses using flow cytometry.
• Improved graft cell survival through immune cell differentiation blockade.

Conclusions

• The zebrafish model is a promising tool for pediatric oncology research.
• Drug response assessment can be effectively conducted in this model.
• Future studies may expand to other types of pediatric tumors.

Frequently Asked Questions